Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
Aged
Angiotensin-Converting Enzyme 2
Antithrombins
/ therapeutic use
Atrial Fibrillation
/ blood
Betacoronavirus
Biomarkers
/ blood
COVID-19
Cohort Studies
Coronavirus Infections
/ blood
Dabigatran
/ therapeutic use
Female
Humans
Male
Middle Aged
Pandemics
Peptidyl-Dipeptidase A
/ blood
Pneumonia, Viral
/ blood
Pyrazoles
/ therapeutic use
Pyridones
/ therapeutic use
Risk Factors
SARS-CoV-2
Stroke
/ prevention & control
Warfarin
/ therapeutic use
ACE2
Age
Atrial fibrillation
Biomarker
COVID-19
Cardiovascular disease
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
01 11 2020
01 11 2020
Historique:
received:
07
05
2020
revised:
25
06
2020
accepted:
12
08
2020
pubmed:
29
9
2020
medline:
27
11
2020
entrez:
28
9
2020
Statut:
ppublish
Résumé
The global COVID-19 pandemic is caused by the SARS-CoV-2 virus entering human cells using angiotensin-converting enzyme 2 (ACE2) as a cell surface receptor. ACE2 is shed to the circulation, and a higher plasma level of soluble ACE2 (sACE2) might reflect a higher cellular expression of ACE2. The present study explored the associations between sACE2 and clinical factors, cardiovascular biomarkers, and genetic variability. Plasma and DNA samples were obtained from two international cohorts of elderly patients with atrial fibrillation (n = 3999 and n = 1088). The sACE2 protein level was measured by the Olink Proteomics® Multiplex CVD II96 × 96 panel. Levels of the biomarkers high-sensitive cardiac troponin T (hs-cTnT), N-terminal probrain natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), C-reactive protein, interleukin-6, D-dimer, and cystatin-C were determined by immunoassays. Genome-wide association studies were performed by Illumina chips. Higher levels of sACE2 were statistically significantly associated with male sex, cardiovascular disease, diabetes, and older age. The sACE2 level was most strongly associated with the levels of GDF-15, NT-proBNP, and hs-cTnT. When adjusting for these biomarkers, only male sex remained associated with sACE2. We found no statistically significant genetic regulation of the sACE2 level. Male sex and clinical or biomarker indicators of biological ageing, cardiovascular disease, and diabetes are associated with higher sACE2 levels. The levels of GDF-15 and NT-proBNP, which are associated both with the sACE2 level and a higher risk for mortality and cardiovascular disease, might contribute to better identification of risk for severe COVID-19 infection.
Identifiants
pubmed: 32984892
pii: 5912214
doi: 10.1093/eurheartj/ehaa697
pmc: PMC7543499
doi:
Substances chimiques
Antithrombins
0
Biomarkers
0
Pyrazoles
0
Pyridones
0
apixaban
3Z9Y7UWC1J
Warfarin
5Q7ZVV76EI
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Dabigatran
I0VM4M70GC
Banques de données
ClinicalTrials.gov
['NCT00262600', 'NCT00412984']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
4037-4046Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Références
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Mucosal Immunol. 2020 May;13(3):437-448
pubmed: 31900405
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
PLoS One. 2014 Apr 01;9(4):e87845
pubmed: 24691269
Eur Heart J. 2020 May 14;41(19):1810-1817
pubmed: 32388565
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1084-H1090
pubmed: 32228252
Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L84-96
pubmed: 19411314
Front Physiol. 2014 Jun 24;5:227
pubmed: 25009501
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
J Med Virol. 2020 Jun;92(6):568-576
pubmed: 32134116
J Virol. 2014 Jan;88(2):1293-307
pubmed: 24227843
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
J Am Coll Cardiol. 2008 Aug 26;52(9):750-4
pubmed: 18718423
J Am Coll Cardiol. 2017 Aug 15;70(7):813-826
pubmed: 28797349
J Clin Pharm Ther. 2018 Apr;43(2):189-195
pubmed: 28895159
Eur Heart J. 2018 Feb 7;39(6):477-485
pubmed: 29069359
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
J Am Coll Cardiol. 2013 Jun 4;61(22):2274-84
pubmed: 23563134
Aging (Albany NY). 2020 Mar 30;12(8):6511-6517
pubmed: 32229706
Bioinformatics. 2014 May 1;30(9):1266-72
pubmed: 24413527
IUBMB Life. 2013 Sep;65(9):731-8
pubmed: 23893738
Circulation. 2012 Apr 3;125(13):1605-16
pubmed: 22374183
Circulation. 2014 Nov 18;130(21):1847-58
pubmed: 25294786
Atherosclerosis. 2016 Oct;253:135-143
pubmed: 27615597
Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S60-8
pubmed: 21342901
PLoS One. 2013 Dec 02;8(12):e78797
pubmed: 24312445
PLoS One. 2018 Jun 13;13(6):e0198144
pubmed: 29897923
Viruses. 2020 Mar 27;12(4):
pubmed: 32230900
Lancet Infect Dis. 2012 Sep;12(9):687-95
pubmed: 22738893
Clin Chem. 2017 Jan;63(1):325-333
pubmed: 27811204
Nat Genet. 2016 Nov;48(11):1443-1448
pubmed: 27694958
J Hypertens. 2012 Feb;30(2):375-83
pubmed: 22179088
J Med Virol. 2020 Jul;92(7):726-730
pubmed: 32221983
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
N Engl J Med. 2008 May 15;358(20):2107-16
pubmed: 18480203
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651